Syndax's new finance chief starts Nov. 9; his predecessor stays through year-end
Syndax Pharmaceuticals (SNDX) appointed Aaron A. Ondrey as CFO, effective Nov. 9, 2026. Keith A. Goldan, the outgoing CFO, will stay until year-end to support the transition. Ondrey has 25 years of biotech finance experience, previously serving as CFO at Beren Therapeutics and Rocket Pharmaceuticals. Goldan led Syndax's financial strategy during key growth periods, including FDA approvals for Revuforj and Niktimvo.
How this was made
The 30-second read
Why it matters
While the appointment is a primary corporate action, it does not contain new financial guidance or deal terms that would drive immediate price movement.
Market read
The news is a corporate action with modest relevance; traders may monitor for any subsequent guidance updates.
What to watch
The CFO's prior experience at Rocket and Mirati may signal upcoming strategic M&A activity that the market has not priced in.
Background
Syndax is a commercial‑stage biopharma with two FDA‑approved cancer therapies. The CFO transition occurs as the company scales its commercial operations.
Ticker impact
Syndax Pharmaceuticals announced the appointment of Aaron A. Ondrey as CFO effective November 9, 2026, replacing retiring CFO Keith A. Goldan.
likely limited pressure or modest upside as investors assess the new CFO's track record
Executive changes are material for long‑term governance but rarely trigger sharp short‑term moves unless accompanied by guidance or a deal.
Market effects
Minimal; CFO change does not materially alter the biotech sector outlook.
None; the news is company‑specific to a US‑listed biotech.
Low; limited broader market impact.
Counterpoint
If the new CFO fails to deliver expected financial discipline, the stock could underperform despite the leadership change.
Key entities
- ExecutiveAaron A. Ondrey
New Chief Financial Officer of Syndax.
- ExecutiveKeith A. Goldan
Outgoing CFO, retiring after tenure.
